(interquartile range 1.1-4.0 years). Participants with IL-6 levels above the median showed greater cognitive decline on the TICS-m compared to those with levels below the median, adjusting for sociodemographic and vascular factors ( ␤ = -0.17 points/year, p = 0.02). Decline on the TICS-m among participants with IL-6 above the median differed by age (p for interaction ! 0.001). There was no interaction by race/ ethnicity, vascular risk factors, C-reactive protein, apolipoprotein 4 allele status, or the metabolic syndrome among nondiabetics. Conclusions: IL-6 associated with cognitive decline among older participants in this racially/ethnically diverse sample independent of other vascular risk factors and C-reactive protein.
Introduction
Interleukin 6 (IL-6) is an inflammatory cytokine linked to dementia, mild cognitive impairment and Alzheimer disease [1] [2] [3] [4] . However, there are conflicting data on the effect of IL-6 on cognitive decline. Several studies have reported an association, but the Dutch Longitudinal Aging Study Amsterdam found IL-6 was not associated with cognitive decline, and the Whitehall II Study found raised levels of IL-6 had an inconsistent association with poor cognitive performance [5] [6] [7] [8] [9] .
The role of traditional vascular risk factors in mediating an association between IL-6 and cognitive decline requires further clarification as well [10] . IL-6 combined with the constellation of risk factors making up the metabolic syndrome may increase the risk of cognitive decline. The Leiden 85-Plus Study found that the combination of cardiovascular disease and a proinflammatory cytokine response may be associated with cognitive impairment [11, 12] . On the other hand, the Edinburgh Artery Study found that IL-6 was associated with cognitive decline independent of cardiovascular disease (CVD) [13] . We have previously reported an inverse association between IL-6 and cognitive performance independent of carotid intima-media thickness, a subclinical marker of CVD [14] . In addition, IL-6 stimulates C-reactive protein (CRP) production, an established marker of cardiovascular risk, but there is conflicting data regarding the association of CRP with cognitive decline in combination with elevated IL-6 [6, 12] . In an African-Caribbean population, IL-6 was associated with cognitive decline, even when adjusted for vascular risk factors; however, CRP was not found to exhibit such an association [15] .
Prospective studies examining the relationship between IL-6 and cognitive function have found conflicting results, and it is unclear if vascular or neurodegenerative processes underlie the associations [5, 7, 9, 11, [13] [14] [15] . In addition, few studies on IL-6 and cognitive decline have included Hispanics and non-Hispanic Blacks who may be at greater risk of dementia than non-Hispanic Whites [10, 16, 17] . We conducted a prospective study of the association between baseline plasma IL-6 levels and cognitive decline, and examined vascular risk factors, apolipoprotein 4 (APOE4) allele status, and inflammation in a stroke-free community-based multiethnic cohort.
Methods

Description of Cohort
The Northern Manhattan Study (NOMAS) includes a prospective cohort of 3,298 stroke-free participants recruited using random digit dialing in northern Manhattan between 1993 and 2001. The details of enrollment are described elsewhere [18] . Briefly, participants were eligible if they met the following conditions: (1) no history of stroke, (2) age 6 40 years and (3) residence in a household with a telephone for at least 3 months in northern Manhattan. Written informed consent was obtained from all participants, and the Columbia University Medical Center and University of Miami Miller School of Medicine Institutional Review Boards approved the study.
Baseline Evaluation and Follow-Up
Trained bilingual research assistants and study physicians collected demographic, medical and laboratory data at enrollment using standardized data collection techniques and risk factor questions. These standardized questions were adapted from the Behavioral Risk Factor Surveillance System regarding the following conditions: hypertension, diabetes mellitus and cigarette smoking [19, 20] . Depressive symptoms were quantified using the Hamilton Depression Scale [21] . Subjects were contacted annually via telephone starting in 1998 to document information regarding illnesses, hospitalizations, vital status and cardiovascular events.
Laboratory Measurements
Serum samples for IL-6 and high-sensitivity CRP (hsCRP) were drawn into EDTA tubes at baseline, spun immediately at 3,000 g at 4 ° C for 20 min, and then frozen at -70 ° C for later analysis. Inflammatory marker levels were then measured in batched samples by enzyme-linked immunosorbent assay using monoclonal antibodies to IL-6 with a lower limit of detection of 0.1 pg/ ml (Biosource International, Camarillo, Calif., USA) and hsCRP with a lower limit of detection of 0.1 mg/l (BioCheck Inc., Foster City, Calif., USA). ApoE 2, 3 and 4 alleles were determined by two single-nucleotide polymorphisms, i.e. rs429358 and rs7412 . The two single-nucleotide polymorphisms were genotyped using TaqMan allelic discrimination assays (Applied Biosystems) following the manufacturer's instructions. 
Cognitive Assessment
Covariates
Established risk factors for cognitive impairment were selected as covariates for multivariable analysis. All variables were assessed at baseline. Race/ethnicity was based on self-identification. Educational status was dichotomized based on whether or not high school had been completed. Insurance status was dichotomized as Medicaid or no insurance versus Medicare or private insurance. A history of depression was defined as a Hamilton Depression Scale score greater than 10 or current antidepressant use. Moderate physical activity was dichotomized as any recreational or physical activity in the prior 2 weeks versus none, according to our validated methods [20] . Diabetes was defined based on the subject's self-reported history, usage of hypoglycemic medications, or fasting blood sugar greater than 126 mg/dl [19, 20] . Smoking status was categorized as never, current (within the last year) or former smoker. Reported alcohol consumption was categorized as moderate (1 drink/week to 2 drinks/day) versus light ( ! 1 drink/week) or nondrinkers. The number of heavy drinkers ( 1 2 drinks/day) was small and was included in the reference category. Metabolic syndrome was defined by ATP III criteria as three of the following: abdominal obesity, raised triglycerides, reduced high-density lipoprotein cholesterol, elevated blood pressure, and raised plasma glucose [24] .
Statistical Analyses
We compared sample characteristics across levels of IL-6 using 2 and Student t tests as appropriate. We used mixed effects models with random intercepts to examine the association between IL-6 levels and cognitive decline measured with the TICSm. There was no graded dose effect across quartiles, but the effect differed at the median split. We therefore created a categorical variable for IL-6 levels above and below the median. To estimate the effect of IL-6 and other covariates on change in TICS-m score over time, we examined the interaction between IL-6 and time between baseline and subsequent TICS-m measurement. The resulting coefficient provides the slope of change of TICS-m scores over time and is a standard approach [25] . In addition to IL-6, we examined the effect of hsCRP on change in TICS-m scores over time as a continuous variable, using quartiles of hsCRP, and using the established cutoffs of 1 3, 1-3 and ! 1 mg/dl. To relate the rate of cognitive decline associated with these biomarkers to age-related change in TICS-m scores in our sample, we also examined age as a predictor of cognitive decline. We looked for effect modification by examining interactions between IL-6, time and other covariates of interest such as age and CRP. Finally, we carried out two subanalyses, one to examine an interaction with metabolic syndrome among participants without diabetes and the other to examine the effect of APOE4 allele status. To allow us to estimate the effect of IL-6 on cognitive decline in a stroke-free population, for the primary analysis participants with stroke prior to the baseline TICS-m were excluded and we censored TICS-m scores acquired after a stroke event.
Results
There were 1,224 NOMAS participants with both IL-6 (median 1.5 pg/ml, interquartile range 0.83-2.57 pg/ml) and TICS-m measurements (overall mean = 31.6 points, SD = 6.5). Baseline characteristics of the sample are shown in to NOMAS participants without these measurements, the current sample included a greater proportion of Hispanics (59 vs. 48%), more participants with a high school education (47 vs. 45%) and fewer people with diabetes (14 vs. 27%). Twenty-two participants were excluded due to stroke prior to baseline TICS-m assessment, and 13 observations were censored after stroke. Compared to those with IL-6 levels below the median, participants with IL-6 levels above the median were older, more likely to have hypertension, the metabolic syndrome, to be women, to have less than a high school education, Medicaid or no insurance, to be current smokers, and to report moderate alcohol consumption ( table 2 ) . Over 3,406 person-years of follow-up (median 3.0 years, interquartile range 1.1-4.0; see table 1 for number of participants with different numbers of TICS-m measurements), we found that participants with IL-6 levels above the median had a greater decline on the TICS-m over time than those with levels below the median ( table 3 ) . This effect was slightly attenuated after adjusting for age, race/ethnicity, education, sex and insurance status but remained significant. The strength of the association between IL-6 and cognitive decline remained unchanged after adjusting for diabetes mellitus, hypertension, physical activity, depression, alcohol consumption and smoking status ( table 3 ) .
We found a significant interaction between IL-6, decline on TICS-m over time, and age ( ␤ = -0.40 points/ year for each additional year of age above the sample mean in those with IL-6 levels above the median compared to below, p for 3-way interaction ! 0.0001). Further stratifying by age, participants older than 71 with IL-6 levels above the median declined by 0.4 points more per year than those with IL-6 levels below the median (p ! Diabetes was defined as a fasting blood glucose of >126 mg/dl or a history of insulin or hypoglycemic use. Moderate alcohol consumption was defined as taking more than 1 alcoholic beverage per month up to 2 per day. Depression was defined as a Hamilton Depression Scale score >10 or current antidepressant use. 0.0001), while in younger participants IL-6 levels were not significantly associated with the rate of cognitive decline. We found no interaction by race/ethnicity or by modifiable vascular risk factors. Our findings were confirmed among a subsample limited to nondiabetics (n = 1,054): those with IL-6 levels above the median still showed a greater rate of decline on the TICS-m than below the median ( ␤ = -0.17 points/year, p = 0.02), and there was no interaction with metabolic syndrome (data not shown). We did not examine the association between IL-6 and change in TICS-m scores among diabetics due to the small sample size (n = 167).
hsCRP (median 2.5 mg/l, interquartile range 1.0-5.7 mg/l) was not associated with cognitive decline on the TICS-m. In addition, change in TICS-m scores did not differ significantly for those with hsCRP levels in any of the upper three quartiles compared to those with hsCRP levels in the lowest quartile (Q4 ␤ = -0.01 points/year; Q3 ␤ = -0.001; Q2 ␤ = 0.05 each compared to Q1, p 1 0.1 for all comparisons) or for those with hsCRP levels 1 3 mg/l ( ␤ = -0.05, p = 0.50), or hsCRP levels between 1 and 3 mg/l ( ␤ = 0.02, p = 0.83), compared to those below 1 mg/l. There was also no interaction between IL-6 and hsCRP in relation to cognitive decline (data not shown).
Examining APOE4 allele carrier status as a possible moderator of the association between IL-6 and TICS-m performance over time among a subgroup for whom allele status was available (n = 817), we included APOE4 as a covariate in our fully adjusted model and the association between IL-6 and cognitive decline diminished and was no longer significant ( ␤ = -0.13, p = 0.1). There was no significant interaction, however, and thus the greater decline in TICS-m scores seen for those with IL-6 levels above the median did not differ by APOE4 status (data not shown).
Finally, to put our findings regarding IL-6 and cognitive decline into perspective, we examined the effect of age on change in TICS-m scores over time. Participant age was associated with a decline of 0.02 points/year (p ! 0.001).
Discussion
Participants with baseline serum IL-6 values above the median had greater cognitive decline than those below the median in this prospective stroke-free racially/ethnically diverse urban US population. The magnitude of decline in TICS-m scores among those with IL-6 levels above the median compared to below the median was equivalent to the average amount of cognitive aging occurring in this sample over about 8 years. Based on a stratified analysis, the effect of IL-6 on cognitive decline was significant only among those older than the mean age of 71, independently of other sociodemographic and vascular risk factors.
The role of IL-6 in cognitive decline is poorly understood, but an association between relative elevations of IL-6 and CVD, as well as CVD risk factors, has been found in prior studies. For example, serum IL-6 levels have been associated with a greater risk of recurrent stroke, as well as greater stroke severity, than lower levels of the marker, but causality in either case has not been determined [26] . The Health, Aging, and Body Composition (Health ABC) study showed that those with the metabolic syndrome were at greater risk of cognitive decline than those without the metabolic syndrome only if they had both CRP and IL-6 levels above the median [11] . In the current study, the association between IL-6 and cognitive decline did not depend on having metabolic syndrome even when restricted to nondiabetics. In addition, hsCRP was not a predictor of cognitive decline in this sample, and there was no interaction between relative elevations of IL-6 and hsCRP and cognitive decline.
We also found that other vascular risk factors did not alter the strength of the association between IL-6 and cognitive decline. The populations in NOMAS and Health ABC are distinct, and we were unable to find studies of the association between IL-6 and cognitive decline that have included large samples of Hispanic people, while the Health ABC study included well-functioning White and African-American elders. In NOMAS the risk of cognitive decline for those with IL-6 levels above the median did not differ by racial/ethnic group. While hypertension is very common among all three racial/ ethnic groups in NOMAS, as in Health ABC, there are some differences as well. For example, high triglycerides and low high-density lipoprotein cholesterol were common among Hispanics but less so for both Whites and Blacks in our sample. Some of these differences may explain disparate findings between these studies regarding the role of IL-6 and cognitive decline. hsCRP is an established inflammatory marker for future vascular disease; however, data on hsCRP in the Hispanic population is scarce. The NOMAS population, of which approximately 52% are Hispanic, had higher hsCRP levels than whites [27] .
It is not clear if IL-6 is playing a role in cognitive dysfunction through vascular damage. A genetic propensity to a heightened inflammatory response predisposing to cognitive impairment has been proposed, however, and some of these studies support a vascular mechanism [11] . We have previously reported that individuals homozygous for the GG genotype at position 174 of the IL-6 gene had greater carotid artery wall thickness, and the Atherosclerosis Risk in Communities Study showed an association between cognitive dysfunction and increased carotid intima-media thickness [28, 29] . However, adjusting for baseline vascular risk factors did not alter the association between IL-6 and cognitive decline in our study, suggesting that a nonvascular mechanism may be operative. Another plausible mechanism by which IL-6 could influence the rate of cognitive decline is through a neurodegenerative process, and one study in a community sample of middle-aged adults has found that elevated plasma IL-6 levels were associated with lower hippocampal gray matter volumes independently of body fat and hypertension [30] . In the current study, adjusting for APOE4 allele status in a subsample attenuated the effect of IL-6 on cognitive decline, and it was no longer significant, suggesting possible mediation. However, there was no significant interaction between IL-6, change in TICS-m scores over time, and APOE4 status. It is likely that our power to detect both the main effect of IL-6 on cognitive decline and the interaction between IL-6 and APOE4 status was limited by the smaller sample size. Larger studies are needed to clarify this finding. Interestingly, the Rotterdam study, contrary to what was hypothesized, found that the risk for dementia with increased levels of IL-6 was independent of atherosclerosis, and the authors proposed a peripheral inflammatory mechanism related to ␤ -amyloid deposition [31] .
An important limitation of this study is that there are limited data showing that IL-6 crosses the blood-brain barrier, and that serum IL-6 may accurately reflect cerebrospinal fluid levels [32] . Another concern is that serum IL-6 levels were measured only at baseline in NOMAS, and thus it is possible that levels changed later. However, studies examining the validity of IL-6 levels show that intraindividual concentrations do not vary much over time, though the time periods examined have been short, and therefore remain an indicator of chronic inflammatory states that both precede and follow the actual measurement [33] [34] [35] . Another concern is that the TICS-m is a global test of cognition and lacks sensitivity for specific domains, such as verbal memory or executive function. However, this would tend to decrease our ability to detect an association between IL-6 and cognition. Further data examining more sensitive neuropsychological tests are warranted. Despite the relatively large sample size, the median follow-up per individual was 3 years and studies with a longer follow-up are needed to confirm our findings. In addition, the study sample lacked enough people with diabetes to assess IL-6 levels and cognitive decline in this group. Despite the limitations, this study also has important strengths, including the large sample size, the population-based multiethnic cohort and the longitudinal design.
Conclusion
In summary, we found that participants in a population-based urban US sample with IL-6 levels above the median had a greater rate of cognitive decline than those with levels below the median. This association was independent of traditional vascular risk factors, and was more pronounced with advancing age. We did not find racial/ ethnic differences in the effect of IL-6 on cognitive decline, and these results are applicable to a racially/ethnically diverse population.
